Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT01937780
Active, not recruiting Observational

Anal Cancer Radiotherapy Study

NCT01937780 · tracked via the Priya Life Science Norway tracker
Sponsor
Oslo University Hospital
Phase
Observational
Started
2013-10-04
Last updated
2025-03-21

Condition(s) studied

Anal Cancer

Study summary

This is a prospective study of patients receiving radiotherapy or chemoradiotherapy for anal cancer. Treatment effect in terms of survival and local recurrence will be analyzed. The utility of PET-CT and MRI for radiotherapy and for prediction of treatment effect will be investigated. Molecular and genetic markers in tumor and blood will be analyzed for prognostic and predictive effects. Patient-reported outcomes, such as faecal incontinence, sexual dysfunction and quality of life will be assessed. A structured intervention program for management of late effects will be evaluated. Symptom relief of palliative radiotherapy will be investigated. The main purpose of the study is to increase the knowledge of anal cancer treatment, improve treatment results, and improve anal cancer survivor care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Histologically verified anal squamous cell carcinoma * Radiotherapy or chemoradiotherapy planned * ECOG performance status 0-2 * \>= 18 years of age * Signed informed consent and expected cooperation of the patients for treatment and follow up Exclusion Criteria: \- Cognitive or physical condition resulting in inability to sign informed consent or cooperation during treatment

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Oslo University Hospital Oslo Norway

More Oslo University Hospital trials in Norway

Early Discovery of Ischemia After Replantation Surgery of the Extremities Active, not recruiting
RAdiotherapy With FDG-PET Guided Dose-PAINTing for Primary Head and Neck Active, not recruiting
A Study of Enalapril in Treatment of Venous Malformations Recruiting
Treatment of Olecranon Fractures in the Elderly Recruiting
A Study of Direct Oral Anticoagulants in Patients with Painful Venous Malformations with Localized Intravascular Coagulation Starting soon

Other trials for the same condition

NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01937780 on ClinicalTrials.gov ↗ ← All trials in Norway